Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

Serina Therapeutics, Inc.

2026-Q1 EPS reported -$0.58

Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.
Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.
SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.
Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.